سعر ايفرينزو 50 مجم 2026

Film-coated tablet containing roxadustat 50 mg; Astellas Pharma product distributed in Egypt by the Egyptian Pharmaceutical Trading Company; pack of 12 tablets.

• Symptomatic anaemia associated with chronic kidney diseasePopulation: AdultsEuropean Medicines Agency (EMA)

• Very common: hypertension, vascular access thrombosis, diarrhoea, peripheral oedema, hyperkalaemia, nausea. Common: sepsis, insomnia, headache, vomiting, constipation, seizures, DVT; others include pulmonary embolism, thrombocytopenia, secondary hypothyroidism.International label, same product · European Medicines Agency (EMA)

• Hypersensitivity to roxadustat, peanut, soya or any excipient; third trimester of pregnancy; breast-feeding.International label, same product · European Medicines Agency (EMA)

• Increased risk of cardiovascular events and mortality; thrombotic vascular events (DVT, pulmonary embolism, vascular access thrombosis) - avoid exceeding Hb targets and monitor.International label, same product · European Medicines Agency (EMA)
• Seizures, serious infections/sepsis and secondary hypothyroidism have been reported; use with caution.International label, same product · European Medicines Agency (EMA)
• Women of childbearing potential must use highly effective contraception during treatment and for at least one week after the last dose.International label, same product · European Medicines Agency (EMA)

• Phosphate binders (sevelamer, calcium acetate) and multivalent cationsModerateReduce roxadustat exposure (sevelamer AUC -67%, calcium acetate -46%); take roxadustat at least 1 hour after.European Medicines Agency (EMA)
• Gemfibrozil, probenecid (CYP2C8/UGT1A9/OAT inhibitors)ModerateIncrease roxadustat AUC about 2.3-fold; monitor Hb and adjust dose.European Medicines Agency (EMA)
• Statins (simvastatin, rosuvastatin, atorvastatin) and other BCRP/OATP1B1 substratesModerateRoxadustat increases statin exposure (e.g. rosuvastatin AUC ~2.9-fold); consider lower statin dose.European Medicines Agency (EMA)

• Animal studies showed reproductive toxicity; contraindicated in the third trimester and not recommended in the first and second trimesters.International label, same product · European Medicines Agency (EMA)
• Contraindicated during breast-feeding (excreted in animal milk).International label, same product · European Medicines Agency (EMA)

• Roxadustat: Reversible inhibitor of HIF prolyl hydroxylase; increases HIF levels, stimulating endogenous erythropoietin production, iron absorption/mobilisation and erythropoiesis (EU SmPC 5.1).